Renaissance Technologies LLC Cuts Stock Position in Supernus Pharmaceuticals, Inc. $SUPN

Renaissance Technologies LLC lessened its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 1.6% in the first quarter, Holdings Channel reports. The institutional investor owned 1,705,222 shares of the specialty pharmaceutical company’s stock after selling 27,300 shares during the period. Renaissance Technologies LLC’s holdings in Supernus Pharmaceuticals were worth $88,143,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in SUPN. Sit Investment Associates Inc. boosted its holdings in Supernus Pharmaceuticals by 0.4% in the fourth quarter. Sit Investment Associates Inc. now owns 65,200 shares of the specialty pharmaceutical company’s stock worth $3,240,000 after acquiring an additional 250 shares in the last quarter. Summit Global Investments grew its stake in shares of Supernus Pharmaceuticals by 6.1% in the first quarter. Summit Global Investments now owns 4,436 shares of the specialty pharmaceutical company’s stock worth $229,000 after acquiring an additional 256 shares during the last quarter. Maryland State Retirement & Pension System increased its holdings in shares of Supernus Pharmaceuticals by 3.6% during the fourth quarter. Maryland State Retirement & Pension System now owns 8,351 shares of the specialty pharmaceutical company’s stock valued at $415,000 after acquiring an additional 290 shares in the last quarter. SummitTX Capital L.P. increased its holdings in shares of Supernus Pharmaceuticals by 2.7% during the fourth quarter. SummitTX Capital L.P. now owns 11,670 shares of the specialty pharmaceutical company’s stock valued at $580,000 after acquiring an additional 303 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its position in shares of Supernus Pharmaceuticals by 2.3% in the 1st quarter. PNC Financial Services Group Inc. now owns 14,548 shares of the specialty pharmaceutical company’s stock worth $752,000 after purchasing an additional 321 shares during the last quarter.

Analyst Upgrades and Downgrades

SUPN has been the topic of a number of analyst reports. Cantor Fitzgerald upped their price target on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a research note on Thursday, July 9th. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Wednesday, June 24th. Finally, Zacks Research upgraded shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Supernus Pharmaceuticals presently has an average rating of “Hold” and an average target price of $62.83.

Supernus Pharmaceuticals Trading Down 2.1%

Supernus Pharmaceuticals stock opened at $46.20 on Friday. Supernus Pharmaceuticals, Inc. has a 12 month low of $32.53 and a 12 month high of $59.68. The stock has a fifty day simple moving average of $46.48 and a two-hundred day simple moving average of $49.24. The firm has a market cap of $2.68 billion, a price-to-earnings ratio of -90.59, a PEG ratio of 0.99 and a beta of 0.54.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.